Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial

Contemporary Clinical Trials(2020)10.1016/j.cct.2020.105938Source: DataRank Database

High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial is a research paper published in Contemporary Clinical Trials (2020). On theSindex it has a DataRank of 2.0. It has been cited 57 times, with 39 citing works in its 1-hop citation network.

N/A

2.0DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access57 citations · 39 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02410772

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (15 grants)OA: greenTopics (112)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 31%Citation Network 69%

Base Score Contribution

0.609

From this paper's citation signal

Citation Network Contribution

1.4

From 33 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 39 citers.

Ending TB: the world’s oldest pandemic
Journal of the International AIDS Society202114 citations14 referencesContributes 0.193
The Right to Science
Cambridge University Press eBooks20215 citations11 referencesContributes 0.163
Turning threats into opportunities: how to implement and advance quality TB services for people with HIV during the COVID‐19 pandemic and beyond
Journal of the International AIDS Society202114 citations27 referencesContributes 0.100
The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the Mycobacterium tuberculosis DprE1 Enzyme
International Journal of Molecular Sciences202221 citations32 referencesContributes 0.097
Tuberculosis in the European Region
Current Tropical Medicine Reports202311 citations27 referencesContributes 0.092

Authors (32)

Payam Nahid ORCID,Ekaterina V. Kurbatova ORCID,Stefan Goldberg ORCID,Lorna Bozeman,William J. Burman ORCID

Live enrichment

PubMed:31981713 PMC:PMC7307310

NIAID NIH HHS

Grant: P30 AI110527

NIAID NIH HHS

Grant: UM1 AI069418

NIAID NIH HHS

Grant: UM1 AI069436

NIAID NIH HHS

Grant: UM1 AI106701

NIAID NIH HHS

Grant: UM1 AI106716

NIAID NIH HHS

Grant: UM1 AI068636

NIAID NIH HHS

Grant: UM1 AI069463

NIAID NIH HHS

Grant: U01 AI069463

NIAID NIH HHS

Grant: UM1 AI068634

NIAID NIH HHS

Grant: UM1 AI108568

NIAID NIH HHS

Grant: U01 AI069436

National Institutes of Health

Grant: 5UM1AI068634-09

Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)

National Institutes of Health

Grant: 3UM1AI068636-19SC

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

National Institutes of Health

Grant: 3UM1AI106701-12S1

AIDS Clinical Trial Group Laboratory Center

National Institutes of Health

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7307310

publisherhttps://api.elsevier.com/content/article/PII:S1551714420300161?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1551714420300161?httpAccept=text/plain

https://doi.org/10.1016/j.cct.2020.105938

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307310

Fields of Study

0301 basic medicine0302 clinical medicine03 medical and health sciences

MeSH Terms

HumansTuberculosis, PulmonaryHIV InfectionsEthambutolRifampinAntitubercular AgentsDirectly Observed TherapyDrug Therapy, CombinationDrug Administration ScheduleAdolescentAdultMiddle AgedFemaleMaleMulticenter Studies as TopicClinical Trials, Phase III as TopicYoung AdultEquivalence Trials as TopicMoxifloxacin

Keywords

TuberculosisMoxifloxacinTbNon-inferiorityRifapentineMulticenter Randomized TrialMaleAntitubercular AgentsHIV InfectionsEthambutol (mesh)Phase III as Topic (mesh)11 Medical and Health Sciences (for)Medical and Health SciencesLung (rcdc)Rifampin (mesh)Clinical Research (rcdc)Multicenter Studies as Topic32 Biomedical and Clinical Sciences (for-2020)Male (mesh)LungGeneral Clinical MedicineHumans (mesh)Young Adult (mesh)3 Good Health and Well Being (sdg)Moxifloxacin (mesh)PulmonaryCombination (mesh)Middle AgedPhase III as TopicInfection (hrcs-hc)Infectious Diseases5.1 Pharmaceuticals6.1 PharmaceuticalsCombinationHIV/AIDSGeneral Clinical Medicine (science-metrix)FemaleDrug Therapy, CombinationPublic HealthRifampinInfectionAntitubercular Agents (mesh)EthambutolAdultAdolescentClinical SciencesClinical Trials and Supportive ActivitiesClinical Trials and Supportive Activities (rcdc)610Directly Observed Therapy (mesh)Equivalence Trials as TopicHIV Infections (mesh)Emerging Infectious Diseases (rcdc)Drug Administration ScheduleRare Diseases (rcdc)Young AdultRare DiseasesDrug TherapyClinical Research5.1 Pharmaceuticals (hrcs-rac)42 Health sciences (for-2020)616Middle Aged (mesh)HumansClinical TrialsTuberculosis, Pulmonary3202 Clinical Sciences (for-2020)HIV/AIDS (rcdc)Public Health (science-metrix)6.1 Pharmaceuticals (hrcs-rac)Biomedical and Clinical SciencesEquivalence Trials as Topic (mesh)Adolescent (mesh)Health sciencesDrug Administration Schedule (mesh)Multicenter Studies as Topic (mesh)Directly Observed TherapyEmerging Infectious DiseasesOrphan DrugGood Health and Well BeingAIDS Clinical Trials Group and the Tuberculosis Trials ConsortiumClinical Trials, Phase III as TopicInfectious Diseases (rcdc)Female (mesh)Orphan Drug (rcdc)Adult (mesh)Pulmonary (mesh)Sexually Transmitted InfectionsTuberculosis (rcdc)Sexually Transmitted Infections (rcdc)

Sustainable Development Goals

SDG 3: 3. Good health